Kalager & Partners
2 December 2025

US Small-Cap Value 50: Risk Analysis

Deep drawdowns during both crises, paired with rapid post-shock recoveries and statistically significant Fama–French five-factor alpha.

20.6%
Ann. Return (2006–2026)
30.9%
Ann. Volatility
0.71
Sharpe Ratio (vs 0.55 Mkt)
0.81 / +11.5%
FF5 R² / Ann. Alpha

Summary

The value screen selects 50 U.S. non-financial small-cap stocks with a market capitalisation of at least $50 million, ranked by price-to-book ratio using point-in-time SEC filings. Each stock starts at an equal 2% weight at the March and September rebalances.

From March 2006 to September 2026, the backtest returned 20.6% a year with 30.9% annualised volatility. Its Sharpe ratio was 0.71, compared with 0.55 for the Fama–French Market Portfolio (11.2% CAGR, 19.6% volatility).

The Fama–French five-factor model explained 81% of daily return variation (R² = 0.81) and left +11.5% annualised alpha (p < 0.001). Use the interactive chart above to switch between the full 20-year sample, the 2006–2015 GFC regime, and the 2016–2026 modern cycle, or toggle to underwater drawdowns.


1. Performance Through Stress: 2006–2015 (GFC & Recovery)

Cheap, cyclical small-cap stocks took heavy losses as credit froze during 2008. Select 2006–2015 in the interactive chart above to inspect the peak-to-trough path and rebound.

  • Drawdown: From July 2007 to November 2008, the portfolio fell 67.4% from peak to trough, compared with 54.6% for the Fama–French Market benchmark.
  • Recovery: The portfolio regained its prior peak in 8.4 months from the trough, compared with 35.7 months for the market benchmark.
  • Factors: Market (+1.06), size (+0.92), value (+0.46) and profitability (+0.14) loadings were all statistically significant (R² = 0.88), with +10.1% annualised alpha (p = 0.002).
  • Returns: The portfolio returned 16.6% a year with 29.8% annualised volatility (Sharpe 0.63 vs. 0.38 market). It finished negative in 6 of 20 half-year periods.

2. Modern Market Regime: 2016–2026 (COVID-19 & Rate Cycles)

The 2016–2019 expansion ended abruptly in March 2020, followed by fiscal stimulus, rising interest rates in 2022–2023, and a mega-cap-led equity rally.

  • Drawdown: The portfolio fell 54.2% from January to March 2020, versus 34.2% for the market benchmark.
  • Recovery: NAV recovered its pre-crash high in 2.6 months, versus 4.4 months for the benchmark.
  • Factors: Market (+1.09), size (+1.11) and value (+0.65) remained the dominant exposures (R² = 0.76), alongside +11.9% annualised alpha (p = 0.013).
  • Returns: The portfolio returned 24.5% a year with 31.8% annualised volatility (Sharpe 0.78 vs. 0.74 market), posting losses in 5 of 22 half-year periods.

Full-Sample & Regime Summary

Metric Full Sample (2006–2026) 2006–2015 Regime 2016–2026 Regime
Annualised Return 20.6% (11.2% Mkt) 16.6% (7.2% Mkt) 24.5% (15.2% Mkt)
Annualised Volatility 30.9% (19.6% Mkt) 29.8% (21.0% Mkt) 31.8% (18.3% Mkt)
Sharpe Ratio 0.71 (0.55 Mkt) 0.63 (0.38 Mkt) 0.78 (0.74 Mkt)
Max Drawdown -67.4% (-54.6% Mkt) -67.4% (-54.6% Mkt) -54.2% (-34.2% Mkt)
Post-Trough Recovery 8.4 months (35.7m Mkt) 8.4 months 2.6 months (4.4m Mkt)
Negative Half-Year Periods 11 / 42 6 / 20 5 / 22
Fama–French 5-Factor R² 0.81 0.88 0.76
FF5 Annualised Alpha +11.5% (p < 0.001) +10.1% (p = 0.002) +11.9% (p = 0.013)

Conclusion

Small-cap value delivered the strongest long-term compounding and highest risk-adjusted return across all four Systematic 50s portfolios, but required enduring 54%–67% drawdowns during liquidity shocks. Comparing these results with US Mid-Cap Value 50 highlights how strongly the value premium concentrates in capacity-constrained smaller stocks.